BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 15093992)

  • 1. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration.
    Tziakas DN; Chalikias GK; Parissis JT; Hatzinikolaou EI; Papadopoulos ED; Tripsiannis GA; Papadopoulou EG; Tentes IK; Karas SM; Chatseras DI
    Int J Cardiol; 2004 Apr; 94(2-3):269-77. PubMed ID: 15093992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S; Kim JO; Methe H
    Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina.
    Tousoulis D; Bosinakou E; Kotsopoulou M; Antoniades C; Katsi V; Stefanadis C
    Int J Cardiol; 2006 Jan; 106(3):333-7. PubMed ID: 16337041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients.
    Huang CY; Wu TC; Lin WT; Leu HB; Lin CP; Lin SJ; Chen JW
    Eur J Clin Invest; 2006 Feb; 36(2):76-84. PubMed ID: 16436088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
    Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG
    J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of matrix metalloproteinases activity in acute myocardial infarction.
    Papadopoulos DP; Moyssakis I; Makris TK; Poulakou M; Stavroulakis G; Perrea D; Votteas VE
    Eur Cytokine Netw; 2005 Jun; 16(2):152-60. PubMed ID: 15941687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinases in isolated hypercholesterolemia.
    Malik J; Stulc T; Ceska R
    Int Angiol; 2005 Sep; 24(3):300-3. PubMed ID: 16158043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level.
    Tousoulis D; Antoniades C; Katsi V; Bosinakou E; Kotsopoulou M; Tsioufis C; Stefanadis C
    Int J Cardiol; 2006 Apr; 109(1):48-52. PubMed ID: 16002160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin.
    Dobreanu M; Dobreanu D; Fodor A; Bacarea A
    Rom J Intern Med; 2007; 45(2):193-9. PubMed ID: 18333374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis.
    Fiedorczyk M; Klimiuk PA; Sierakowski S; Gindzienska-Sieskiewicz E; Chwiecko J
    J Rheumatol; 2006 Aug; 33(8):1523-9. PubMed ID: 16881109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
    Vandooren B; Kruithof E; Yu DT; Rihl M; Gu J; De Rycke L; Van Den Bosch F; Veys EM; De Keyser F; Baeten D
    Arthritis Rheum; 2004 Sep; 50(9):2942-53. PubMed ID: 15457463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction.
    Stumpf C; Petzi S; Seybold K; Wasmeier G; Arnold M; Raaz D; Yilmaz A; Daniel WG; Garlichs CD
    Clin Sci (Lond); 2009 Jan; 116(1):45-52. PubMed ID: 18459941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Sasiela WJ; Szarek M; Ganz P; Libby P;
    Circulation; 2004 Jul; 110(4):386-91. PubMed ID: 15262833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in inflammatory and thrombotic markers between unstable angina and acute myocardial infarction.
    Tousoulis D; Antoniades C; Bosinakou E; Kotsopoulou M; Tsoufis C; Marinou K; Charakida M; Stefanadi E; Vavuranakis M; Latsios G; Stefanadis C
    Int J Cardiol; 2007 Feb; 115(2):203-7. PubMed ID: 16787670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina.
    Furenes EB; Arnesen H; Solheim S; Grøgaard HK; Hoffmann P; Seljeflot I
    Thromb Res; 2009 Nov; 124(5):560-4. PubMed ID: 19410278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokines in patients with ischaemic heart disease or myocardial infarction.
    Bossowska A; Kiersnowska-Rogowska B; Bossowski A; Galar B; Sowiński P
    Kardiol Pol; 2003 Aug; 59(8):105-14. PubMed ID: 14560325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation between upregulation of CD40 system and complex stenosis morphology in patients with acute coronary syndrome.
    Yan JC; Wu ZG; Kong XT; Zong RQ; Zhan LZ
    Acta Pharmacol Sin; 2004 Feb; 25(2):251-6. PubMed ID: 14769218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome.
    Gómez-Hernández A; Sánchez-Galán E; Ortego M; Martín-Ventura JL; Blanco-Colio LM; Tarín-Vicente N; Jiménez-Nacher JJ; López-Bescos L; Egido J; Tuñón J
    Am J Cardiol; 2008 Jul; 102(1):12-8. PubMed ID: 18572029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of interleukin (IL)-13, IL-17 and IL-18 in patients with ischemic heart disease.
    Jafarzadeh A; Esmaeeli-Nadimi A; Nough H; Nemati M; Rezayati MT
    Anadolu Kardiyol Derg; 2009 Apr; 9(2):75-83. PubMed ID: 19357047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
    Patti G; Pasceri V; Colonna G; Miglionico M; Fischetti D; Sardella G; Montinaro A; Di Sciascio G
    J Am Coll Cardiol; 2007 Mar; 49(12):1272-8. PubMed ID: 17394957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.